Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) SVP Paul M. Silva sold 4,213 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $153.41, for a total value of $646,316.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up $3.12 during midday trading on Wednesday, hitting $157.26. The company had a trading volume of 1,901,860 shares, compared to its average volume of 2,090,000. The company has a quick ratio of 4.58, a current ratio of 4.79 and a debt-to-equity ratio of 0.01. The stock has a market cap of $39,770.00, a PE ratio of 80.65, a P/E/G ratio of 2.21 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a 1 year low of $84.39 and a 1 year high of $174.96.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.08. The firm had revenue of $651.63 million during the quarter, compared to analysts’ expectations of $592.49 million. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. The firm’s quarterly revenue was up 42.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.35 EPS. analysts predict that Vertex Pharmaceuticals Incorporated will post 1.63 EPS for the current year.

Vertex Pharmaceuticals announced that its Board of Directors has authorized a share repurchase program on Wednesday, January 31st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the pharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Verition Fund Management LLC lifted its stake in shares of Vertex Pharmaceuticals by 8.4% during the 2nd quarter. Verition Fund Management LLC now owns 3,693 shares of the pharmaceutical company’s stock worth $476,000 after purchasing an additional 287 shares during the last quarter. Grandfield & Dodd LLC lifted its stake in shares of Vertex Pharmaceuticals by 5.9% during the 3rd quarter. Grandfield & Dodd LLC now owns 6,145 shares of the pharmaceutical company’s stock worth $934,000 after purchasing an additional 340 shares during the last quarter. First Republic Investment Management Inc. lifted its stake in shares of Vertex Pharmaceuticals by 2.8% during the 3rd quarter. First Republic Investment Management Inc. now owns 12,643 shares of the pharmaceutical company’s stock worth $1,922,000 after purchasing an additional 346 shares during the last quarter. Atria Investments LLC lifted its stake in shares of Vertex Pharmaceuticals by 7.9% during the 4th quarter. Atria Investments LLC now owns 4,765 shares of the pharmaceutical company’s stock worth $714,000 after purchasing an additional 350 shares during the last quarter. Finally, Advantus Capital Management Inc raised its stake in Vertex Pharmaceuticals by 1.5% in the third quarter. Advantus Capital Management Inc now owns 25,555 shares of the pharmaceutical company’s stock valued at $3,885,000 after buying an additional 369 shares during the last quarter. Hedge funds and other institutional investors own 92.84% of the company’s stock.

Several equities analysts have commented on VRTX shares. HC Wainwright reaffirmed a “hold” rating and issued a $103.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday. Maxim Group reaffirmed a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. Deutsche Bank started coverage on Vertex Pharmaceuticals in a research report on Tuesday, December 12th. They issued a “buy” rating and a $175.00 price objective on the stock. Royal Bank of Canada reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. Finally, Oppenheimer upped their price objective on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and twenty-five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $183.11.

TRADEMARK VIOLATION NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) SVP Paul M. Silva Sells 4,213 Shares” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/14/vertex-pharmaceuticals-incorporated-vrtx-svp-paul-m-silva-sells-4213-shares.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.